Background: As the number of patients requiring extracorporeal membrane oxygen-
| Patient 2
A 50-year-old male with a history of ischemic cardiomyopathy, underwent an orthotopic heart transplant. Intraoperatively, persistent hypotension and hemodynamic instability prompted IABP and ECMO insertion (18F common femoral arterial cannula, 9F SFA distal perfusion, 21F multistage common femoral venous cannula). Over the next several days, the patient's hemodynamics improved, and he was successfully weaned from ECMO and decannulated on POD#7.
The patient remained hospitalized for 20 days total and was discharged in stable condition. Approximately 1 year later, the patient was admitted due to acute allograft rejection complicated by ventricular tachycardia. Upon admission, he was hemodynamically stable, but developed cardiogenic shock requiring defibrillation. He was treated with plasmapheresis, solumedrol, and intravenous immunoglobulin.
Over the next few days, he experienced recurrent ventricular tachycardia and was placed on VA ECMO (18F common femoral arterial cannula, 9F SFA distal perfusion, 21F multistage common femoral venous cannula) for support. As a bridge to re-transplantation, he ultimately underwent total artificial heart (SynCardia, Tuscon, AZ) placement and ECMO decannulation. He remained hospitalized until repeat orthotopic heart transplant on hospital Day 107, and was discharged in stable condition on hospital Day 124.
| Patient 3
A 63-year-old male with a history of ischemic cardiomyopathy had an out-of-hospital cardiac arrest, CPR, and defibrillation, and was transfered to an outside facility. He developed recurrent ventricular fibrillation, was stabilized and was transferred to our facility for advanced heart failure therapies. Two days after transfer, he had a pulseless electrical activity arrest, and he was placed emergently on V-A ECMO (18F common femoral arterial cannula, 9F SFA distal perfusion, 
| Patient 4
A 65-year-old male with a history of ischemic cardiomyopathy was admitted due to ventricular tachycardia and acute on chronic heart failure. He underwent attempted ablation for recurrent ventricular tachycardia, and the ablation was aborted due to development of cardiogenic shock. He was emergently placed on VA ECMO (18F 
| Patient 6
The patient was a 63-year-old male admitted due to chest pain and STEMI. He was taken for left heart catheterization (LHC). During the LHC, he became unstable, had a cardiac arrest, and regained spontaneous circulation after 10 min of CPR and ACLS protocol. An 
| RESULTS
The data are summarized in Tables 1 and 2 . Of 246 patients in the review, 2.4% (6/246) were REPs. All REPs were male, and the median age was 61 years old (42-67). There was no significant difference between median age and sex for REPs or non-REPs (P = 0.751 and P = 0.342). All patients required repeat support for a cardiac etiology, most commonly cardiogenic shock (50%). The type of support deployed varied, with 66.6% (4/6) of patients requiring purely VA ECMO, and the remainder requiring pRVADs with an in-line oxygenator. There was no significant difference between the type of support 
| DISCUSSION
Median hospital length of stay for patients who underwent repeat ECMO support was significantly longer. Patients who require mechanical hemodynamic support multiple times will require a longer hospital stay before they can be safely discharged. This remains a consideration when selecting patients for repeat ECMO support.
The lack of difference between age, sex, and type of support underscores the similarity of REP demographics with our overall ECMO population. Survival data were not statistically significant for
REPs. There were no statistically significant differences between overall mortality, 30 day mortality or length of ECMO runs. Contrary to expectations, the repeat ECMO patients did not have worse outcomes.
This suggests that indications for a second period of ECMO support should be the same as those for the initial indications to initiate ECMO.
There is a relative paucity of data with regards to adult patients requiring repeat support. The largest published population of patients with repeat ECMO support documented a 33.3% overall survival rate for two runs in a series of 86 patients. 5 In our series, the majority of REPs were patients requiring VA ECMO after cardiogenic shock, which often has a poorer prognosis than VV ECMO, with an overall survival of 41%. 6 The etiology for the need for repeat ECMO support plays a significant role in prognosis and outcomes. 6 A larger patient population will be necessary to better determine which types of patients will best benefit from repeat ECMO support. Nevertheless, our results suggest that repeat ECMO support will have a role in patients who require additional mechanical support for recurrent episodes of hemodynamic instability. This will be an area of future evaluation, as ECMO indications are expanded.
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